Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pembrolizumab
Find trials that include:  Any drugs shown
Results 1-25 of 98 for your search:
Start Over
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-040, NCI-2014-02662, 2014-001749-26, NCT02252042
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-054, NCI-2015-01366, 1325-MG, 2014-004944-37, NCT02362594
High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients with Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1404, NCI-2014-02676, NCT02506153
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Pembrolizumab, Combination Chemotherapy, and Celecoxib in Treating Patients with Advanced Colorectal, Appendix, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Pembrolizumab, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1454GCC, NCI-2015-01784, GCC1454 / HP-00061522, HP-00061522, HCR-HP-00061522-1, NCT02289222
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201501072, NCI-2015-00119, 14-x326, NCT02311582
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS142-03, NCI-2015-02095, NCT02325557
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Phase: Phase II, Phase I
Type: Treatment
Age: 6 months to less than 18 years
Trial IDs: 3475-051, NCI-2015-00528, 2014-002950-38, NCT02332668
ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UCC Subjects
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: HCRN GU14-188, NCI-2015-01257, NCT02365766
Carboplatin and Nab-paclitaxel with Pembrolizumab in Treating Patients with Stage IIIB or IV Non-small Cell Lung Cancer That is Unable To Be Removed with Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14L01, NCI-2015-00617, HCRN LUN13-175, LUN13-175, NCI-2015-00449, NCT02382406
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SNDX-275-0601, NCI-2015-01180, NCT02437136
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients with Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-1020, NCI-2015-01505, NCT02444741
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7389-M001-218, NCI-2015-01436, KEYNOTE-150, NCT02513472
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201CIT, NCI-2015-01515, NCT02467361
Start Over